Mallinckrodt plc Announces Poster Presentation on TERLIVAZ® at The Liver Meeting

DUBLIN, Nov. 18, 2024 /PRNewswire/ —

Mallinckrodt plc, a global specialty pharmaceutical company, presented a poster on TERLIVAZ® (terlipressin) for injection in patients with hepatorenal syndrome (HRS) with rapid reduction in kidney function at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), held in San Diego, CA from November 15-19, 2024.

Impact of Waiting until Day 4 for Assessment

One of the key findings of the poster presentation was the evaluation of the potential impact of waiting until Day 4 (and after 12 doses of TERLIVAZ) before assessing outcomes in adult patients with HRS with rapid reduction in kidney function. This is significant because this patient population requires timely and effective treatment to prevent further complications and improve outcomes.

TERLIVAZ is the first and only FDA-approved product indicated to improve kidney function in adults with HRS with rapid reduction in kidney function, an acute and life-threatening condition necessitating hospitalization. The rapid reduction in kidney function variant of HRS is considered rare, affecting more than 42,000 Americans annually, or approximately 0.01% of the U.S. population, with hospitalization rates on the rise.

Limitation of Use and Important Safety Information, including Boxed Warning, should be carefully considered by healthcare professionals and patients.

Impact on Individuals

For individuals diagnosed with HRS with rapid reduction in kidney function, the findings from the poster presentation suggest that waiting until Day 4 for assessment after receiving 12 doses of TERLIVAZ could have a significant impact on treatment outcomes. Patients and healthcare providers should be aware of the importance of timely intervention to improve kidney function and overall prognosis.

Global Impact

The research presented in the poster has implications beyond individual patients, as it highlights the need for effective and timely interventions for rare conditions like HRS with rapid reduction in kidney function. By optimizing treatment strategies and outcomes in these patients, healthcare systems worldwide can better manage this life-threatening condition and improve overall patient outcomes.

Conclusion

The poster presentation on TERLIVAZ at The Liver Meeting underscores the significance of timely assessment and intervention in adult patients with HRS with rapid reduction in kidney function. By evaluating the potential impact of waiting until Day 4 for assessment, the study provides valuable insights for healthcare professionals and patients alike, aiming to improve outcomes in this rare and challenging condition.